In the subgroup analysis discerning early-onset and late-onset MG, coherent patterns emerged (Fig. 3), For instance, a 1 SD increase in genetically predicted CDC42BPB expression levels was associated with elevated risk for both early-onset MG (OR = 2.065; 95% CI 1.322–3.225; P = 1.433 × 10–3) and late-onset MG (OR = 1.578; 95% CI 1.191–2.092; P = 1.506 × 10–3) risk. This evidence concerns the gene CDC42BPB and myasthenia gravis.